Clinical Thrombosis Service
Patient AppointmentsTel: +61 3 9076 2828 /2857 /2858
Fax: +61 3 9076 8500
1st floor South Block
[William Buckland Radiotherapy centre]
Tel: +61 3 9076 2828
Fax: +61 3 9076 8500
Prof Huyen Tran
MBBS (Hons), Master Clin Epi, FRACP, FRCPA
- Dr Mandy Davis
MBBS (Hons), FRACP, FRCPA
- Dr James McFadyen
MBBS (Hons), FRACP
A/Prof Harry Gibbs
The aim of the Clinical Thrombosis Service (CTS) is to provide comprehensive care for patients with venous thrombosis. The CTS is one of the core services of Alfred Health's Department of Haematology, and also undertakes clinical thrombosis research as part of the Australian Centre for Blood Diseases, Monash University.
Clinical focus & Service Provision
The CTS provides care for all aspects of patients with venous thromboembolism (VTE), starting from the diagnosis, acute treatment, investigation for heritable and acquired tendencies for VTE, management of post thrombotic syndrome among patients with deep vein thrombosis (DVT), and evaluation for duration of anticoagulation.
In addition we provide a consultative service to other specialties and provide leadership in antithrombotic therapy within The Alfred and to community based private practitioners.
Patients are referred to us for treatment from numerous centres within Melbourne and regional Victoria.
Venous thromboembolism including DVT and PE represents a significant disease burden and source of morbidity and mortality in Australia and worldwide. The aims of our research on clinical thrombosis are:
- Better define the incidence, natural history and clinical outcome of VTE
- Provide information on the range of therapeutic strategies being employed in the treatment of VTE patients
- Explore factors influencing clinical outcomes
- Better define optimal management of VTE patients
- Inform and inspire future hypothesis driven research in this area
[Photo to be included]
Research Projects and Opportunities
- Venous thromboembolism cohort study
- Post-thrombotic syndrome and venous ulcer following deep vein thrombosis
- The efficacy and safety of Two Weeks of Low Molecular Weight Heparin or Rivaroxaban for Distal Vein Thrombosis
- Incidence of venous thrombosis among patients with haematological malignancies
- The management and outcome of major bleeding among patients receiving novel oral anticoagulants and warfarin
- Oral vitamin K and warfarin reversal for invasive procedures
McFadyen JD, Tran, H, Kaplan ZS. Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A, British Journal of Haematology, 2016,
Bhave P, McGiffin D, Shaw J, Walsh M K, McCarthy P, Tran H A & Davis A K. A guide to performing cardiac surgery in patients with hereditary bleeding disorders. Journal of Cardiac Surgery. 2015, 30(1): 61-69.
French S, Arthur, J F, Tran HA & Hamilton J R. Approval of the first protease-activated receptor antagonist: rationale, development, significance, and considerations of a novel anti-platelet agent. Blood Reviews. 2015, 29(3): 179-189.
Bouchard J, Ghannoum M, Bernier-Jean A, Williamson DR, Kershaw G, Weatherburn C, Eris JM, Tran HA, Patel JP & Roberts DM. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. Clinical Toxicology, 2015, 53(3) 156-163.
Cohen A, Jeyaindran S, Kim JY, Park K, Sompradeekul S, Tambunan KL, Tran HA, Tsai I-C, Ward C. & Wong R. Treating pulmonary embolism in Pacific Asia with direct oral anticoagulants. Thrombosis Research. 2015, 136(2) 196-207.